[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f07d209bcc4eadc6963027cee7a95932952429f75be4137de905e72ae94805b6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742488920,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 133304066,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f07d209bcc4eadc6963027cee7a95932952429f75be4137de905e72ae94805b6"
    }
  },
  {
    "ts": null,
    "headline": "Invesco American Franchise Fund Q4 2024 Commentary",
    "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
    "url": "https://finnhub.io/api/news?id=0cd13fc08d4ce6b9816bba245a2003d62ea169e7a9e1c8f3ac7b61ca90aa6b57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742462400,
      "headline": "Invesco American Franchise Fund Q4 2024 Commentary",
      "id": 133274172,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453695647/image_1453695647.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
      "url": "https://finnhub.io/api/news?id=0cd13fc08d4ce6b9816bba245a2003d62ea169e7a9e1c8f3ac7b61ca90aa6b57"
    }
  },
  {
    "ts": null,
    "headline": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
    "summary": "Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.",
    "url": "https://finnhub.io/api/news?id=e85bac298831e78bf22d36204f1aee651ea7c16900fc03b351b6aff432769054",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461785,
      "headline": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
      "id": 133325925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.",
      "url": "https://finnhub.io/api/news?id=e85bac298831e78bf22d36204f1aee651ea7c16900fc03b351b6aff432769054"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Health Care Fund Q4 2024 Commentary",
    "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
    "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461500,
      "headline": "Invesco Health Care Fund Q4 2024 Commentary",
      "id": 133273550,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
      "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    }
  }
]